Skip to main content
OpenTrials

Clinical trial condition

Head and Neck Squamous Cell Carcinoma

Explore clinical trials studying Head and Neck Squamous Cell Carcinoma. Study availability and eligibility vary by location and protocol.

354 public trials 125 recruiting studies
Refine in advanced search Browse all conditions

Head and Neck Squamous Cell Carcinoma trial results

Completed

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

NCT05077709

Conditions
Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, +16 more
Locations
  • City of Hope Duarte, California, United States
  • UC Davis Cancer Center Sacramento, California, United States
  • University of California San Diego San Diego, California, United States
  • Mid Florida Hematology and Oncology Center Orange City, Florida, United States
View all 21 locations
View Trial Details
Completed

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

NCT05523323

Conditions
Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +6 more
Locations
  • Anhui Cancer Hospital-Radiology Department ( Site 3333) Hefei, Anhui, China
  • Beijing Tongren Hospital affiliated to Capital Medical University ( Site 3343) Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital ( Site 3314) Beining, Beijing Municipality, China
  • Peking Union Medical College Hospital ( Site 3304) Bejiing, Beijing Municipality, China
View all 28 locations
View Trial Details
Completed

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

NCT03082534

Conditions
Carcinoma, Carcinoma, Squamous Cell, Cutaneous Squamous Cell Carcinoma, +37 more
Locations
  • UCSD Moores Cancer Center La Jolla, California, United States
  • University of California Los Angeles Cancer Center Los Angeles, California, United States
  • University of Michigan Cancer Center Ann Arbor, Michigan, United States
  • Washington School of Medicine Cancer Center St Louis, Missouri, United States
View Trial Details

Related conditions